LI
NKTR icon

LRI Investments’s Nektar Therapeutics NKTR Stock Holding History

LRI Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Hold
1
– – ﹤0.01% 1878
2026
Q1 		$72 Hold
1
– – ﹤0.01% 1408
2025
Q4 		$42 Hold
1
– – ﹤0.01% 1346
2025
Q3 		$57 Hold
1
– – ﹤0.01% 1299
2025
Q2 		$26 Hold
1
– – ﹤0.01% 1259
2025
Q1 		$11 Buy
+1
New +$13 ﹤0.01% 1207

Other funds holding NKTR

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

LRI Investments's NKTR Position: Q2 2026 in Review

LRI Investments held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 1 share worth $70. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

LRI Investments first reported a position in NKTR in Q1 2025 and has held it in 6 quarters since. The position peaked at $72 in Q1 2026. 29 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • LRI Investments held 1 share of Nektar Therapeutics worth $70 as of Q2 2026.
  • LRI Investments left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1878 holding.
  • LRI Investments first reported a position in Nektar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • LRI Investments's Nektar Therapeutics position peaked at $72 in Q1 2026.
  • 29 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.